KRAKOW, Poland, March 27, 2025 /PRNewswire/ -- Selvita S.A. (WSE: SLV), one of Europe's leading preclinical CROs, has announced its financial results for 2024 and provided an update on its backlog for 2025. Key Highlights: In Q4 2024, Selvita generated EUR 22.5 million in commercial...
Hence then, the article about selvita reports rebound in h2 2024 and 11 increase in backlog for 2025 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Selvita Reports Rebound in H2 2024 and 11% Increase in Backlog for 2025 )
Also on site :
- ‘The agency just can’t achieve what is required’: The cyclospora outbreak came after the FDA conducted nearly 35% less foreign food inspections
- Danielle Deadwyler, Ella Beatty, Ike Barinholtz, Connor Storrie & More Confirmed For Focus Features’ ‘The Bell Jar’ As Production Wraps
- 9 Years Ago, a Stephen King Adaptation Became the Highest-Grossing Horror Movie Ever — And Still Holds the Title